Resverlogix: The Future of Drug Development

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.